Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

40.04
+0.37000.93%
Post-market: 40.840.8000+2.00%19:59 EDT
Volume:786.77K
Turnover:31.56M
Market Cap:3.85B
PE:-20.47
High:40.46
Open:39.73
Low:39.12
Close:39.67
52wk High:40.58
52wk Low:23.23
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.88
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.22
PE(LYR):-31.16

Loading ...

IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate

Benzinga Earnings
·
Aug 04

Ideaya Q2 FY26 Net Loss Widens to $112.45 Million; Revenue Rises 35.02% to $8.86 Million vs Q1 FY26

Reuters
·
Aug 04

Ideaya Biosciences Q2 Operating Expenses USD 131.148 Million

THOMSON REUTERS
·
Aug 04

Press Release: Ideaya Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 04

Ideaya Biosciences Grants 260,200 Inducement Stock Options at $36.4 Per Share

Reuters
·
Jul 31

Ideaya Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 31

Will IDEAYA’s (IDYA) IDE892 Combo Strategy in MTAP‑Deleted Cancers Reshape Its Targeted Oncology Narrative?

Simply Wall St.
·
Jul 30

IDEAYA Biosciences: Buy Rating Reiterated as Precision Oncology Pipeline Advances and $62 Price Target Maintained

TIPRANKS
·
Jul 27

Ideaya Biosciences initiates monotherapy expansion in IDE892 trial

TIPRANKS
·
Jul 27

Ideaya Begins Phase 1/2 Part 2 Monotherapy Expansion of Ide892 in MTAP-deleted Pancreatic, Lung Cancers

Reuters
·
Jul 27

Ideaya Biosciences Announces Ide892, a Potential Best-in-Class Mta-Cooperative Prmt5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in Mtap-Deleted Pancreatic and Lung Cancers

THOMSON REUTERS
·
Jul 27

Ideaya Shares ESMO 2026 Data Updates for Darovasertib Trials in Uveal Melanoma

Reuters
·
Jul 17

Ideaya Biosciences Chief Accounting Officer Andres Ruiz Briseno Sells 9,550 Shares for $382,131.94

Reuters
·
Jul 10

Ideaya Biosciences price target lowered to $63 from $65 at Truist

TIPRANKS
·
Jul 07

Ideaya Biosciences is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 07

RBC Capital Adjusts IDEAYA Biosciences Price Target to $48 From $53, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Ideaya Biosciences Grants Inducement Stock Options for 98,000 Shares at $36.29 Each

Reuters
·
Jun 26

Ideaya Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jun 26

IDEAYA Biosciences Shareholders Back Leadership, Governance Changes

TIPRANKS
·
Jun 24

IDEAYA Biosciences shareholders ratified PwC as auditor for 2026

Reuters
·
Jun 24